Research Topic · Peer-Reviewed

Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia (CML) is a type of cancer of the blood and bone marrow that affects the myeloid line of blood cells. It is usually caused by the abnormal growth of a gene, called BCR-ABL, which disrupts the process of producing new blood cells. Symptoms of CML can include fever, night sweats, weight los…

Curated from this journal's research 📚 3 peer-reviewed articles cited Cited 14× across the literature 🗓 Reviewed June 2026

Overview

Chronic Myelogenous Leukemia (CML) is a type of cancer of the blood and bone marrow that affects the myeloid line of blood cells. It is usually caused by the abnormal growth of a gene, called BCR-ABL, which disrupts the process of producing new blood cells. Symptoms of CML can include fever, night sweats, weight loss, fatigue, and an enlarged spleen. Treatment options for CML include targeted therapy drugs, such as imatinib, and bone marrow or stem cell transplants. CML is a serious condition but can be effectively treated if caught in time, making early detection and accurate diagnosis of utmost importance.

Research published in this journal

3 peer-reviewed articles, ranked by relevance. Each links to its DOI.

How this research is being cited

The 3 articles above have been cited 14 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.

A sample of recent works citing this journal's research on Chronic Myelogenous Leukemia, linking to each citing work.

Editorial oversight

Curated from peer-reviewed research published in Advances in Leukemia.

Journal editorial board
Hang Su · United States Ewelina Grywalska · Poland Antonio Ruggiero · Italy

This page summarises published research for orientation; it is not medical or professional advice.